DK0998501T3 - Kationiske polymerer, komplekser, som associerer de kationiske polymerer og terapeutisk aktive substanser, der omfatter mindst én negativ ladning, især nukleinsyrer, og anvendelse i genterapi - Google Patents
Kationiske polymerer, komplekser, som associerer de kationiske polymerer og terapeutisk aktive substanser, der omfatter mindst én negativ ladning, især nukleinsyrer, og anvendelse i genterapiInfo
- Publication number
- DK0998501T3 DK0998501T3 DK98939713T DK98939713T DK0998501T3 DK 0998501 T3 DK0998501 T3 DK 0998501T3 DK 98939713 T DK98939713 T DK 98939713T DK 98939713 T DK98939713 T DK 98939713T DK 0998501 T3 DK0998501 T3 DK 0998501T3
- Authority
- DK
- Denmark
- Prior art keywords
- cationic polymers
- gene therapy
- negative charge
- therapeutically active
- associate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F126/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
- C08F126/02—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F8/00—Chemical modification by after-treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Polymers & Plastics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9709209A FR2766194A1 (fr) | 1997-07-21 | 1997-07-21 | Polymeres cationiques, complexes associant lesdits polymeres cationiques et des substances therapeutiquement actives comprenant au moins une charge negative, notamment des acides nucleiques, et leur utilisation en therapie genique |
| FR9715807A FR2766195A1 (fr) | 1997-07-21 | 1997-12-12 | Polymeres cationiques, complexes associant lesdits polymeres cationiques et des substances therapeutiquement actives comprenant au moins une charges negative, notamment des acides nucleiques, et leur utilisation en therapie genique |
| PCT/FR1998/001581 WO1999005183A1 (fr) | 1997-07-21 | 1998-07-20 | Polymeres cationiques, complexes associant lesdits polymeres cationiques et des substances therapeutiquement actives comprenant au moins une charge negative, notamment des acides nucleiques, et leur utilisation en therapie genique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0998501T3 true DK0998501T3 (da) | 2002-07-01 |
Family
ID=26233691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK98939713T DK0998501T3 (da) | 1997-07-21 | 1998-07-20 | Kationiske polymerer, komplekser, som associerer de kationiske polymerer og terapeutisk aktive substanser, der omfatter mindst én negativ ladning, især nukleinsyrer, og anvendelse i genterapi |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6407178B1 (da) |
| EP (1) | EP0998501B1 (da) |
| JP (1) | JP2001510863A (da) |
| AT (1) | ATE215099T1 (da) |
| AU (1) | AU740392B2 (da) |
| CA (1) | CA2297487A1 (da) |
| DE (1) | DE69804463T2 (da) |
| DK (1) | DK0998501T3 (da) |
| ES (1) | ES2172180T3 (da) |
| FR (1) | FR2766195A1 (da) |
| PT (1) | PT998501E (da) |
| WO (1) | WO1999005183A1 (da) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030134420A1 (en) * | 2000-02-18 | 2003-07-17 | Lollo Charles Peter | Methods and compositions for gene delivery |
| WO2002032396A2 (en) * | 2000-10-16 | 2002-04-25 | Massachusetts Institute Of Technology | Lipid-protein-sugar particles for delivery of nucleic acids |
| AU2002257145B2 (en) * | 2001-04-18 | 2005-06-02 | Genzyme Corporation | Method for lowering serum glucose |
| AU2003240978A1 (en) * | 2002-05-31 | 2003-12-19 | Genteric, Inc. | Multi-functional polyamines for delivery of biologically-active polynucleotides |
| US20040077888A1 (en) * | 2002-05-31 | 2004-04-22 | The Regents Of The University Of California | Polyamine-mediated transfection |
| DE10310196A1 (de) * | 2003-03-06 | 2004-09-23 | Rina-Netzwerk Rna Technologien Gmbh | Verwendung eines trizyklischen Antidepressivums zur Förderung der Endozytose |
| AU2004260935A1 (en) * | 2003-06-30 | 2005-02-10 | Canji, Inc. | Polymer encapsulation of adenoviruses |
| CA2543257C (en) | 2003-10-24 | 2013-12-31 | Gencia Corporation | Methods and compositions for delivering polynucleotides |
| US20090123468A1 (en) | 2003-10-24 | 2009-05-14 | Gencia Corporation | Transducible polypeptides for modifying metabolism |
| US8507277B2 (en) | 2003-10-24 | 2013-08-13 | Gencia Corporation | Nonviral vectors for delivering polynucleotides |
| US8062891B2 (en) | 2003-10-24 | 2011-11-22 | Gencia Corporation | Nonviral vectors for delivering polynucleotides to plants |
| US8133733B2 (en) | 2003-10-24 | 2012-03-13 | Gencia Corporation | Nonviral vectors for delivering polynucleotides to target tissues |
| US20070176158A1 (en) * | 2006-02-01 | 2007-08-02 | Robinson Jeffery A | Portable safety barrier |
| US8686129B2 (en) * | 2007-03-20 | 2014-04-01 | Agilent Technologies, Inc. | Methods for the separation of biological molecules using sulfolane |
| US8357531B2 (en) | 2007-07-03 | 2013-01-22 | Transgene S.A. | Immortalized avian cell lines |
| CN101970012A (zh) * | 2007-09-14 | 2011-02-09 | 日东电工株式会社 | 药物载体 |
| US8722348B2 (en) * | 2008-05-28 | 2014-05-13 | Wayne State University | Method and composition for a protein transduction technology and its applications |
| AU2015270888B2 (en) * | 2008-05-28 | 2017-11-16 | Wayne State University | Method and composition for a protein transduction technology and its applications |
| CA2934065C (en) | 2013-10-25 | 2023-05-09 | Qurgen, Inc. | Methods, systems and compositions relating to cell conversion via protein-induced in-vivo cell reprogramming |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3440320A (en) * | 1964-06-18 | 1969-04-22 | Mortimer D Sackler | Chelated suppository and method of using same |
| US3325472A (en) * | 1964-06-18 | 1967-06-13 | Mortimer D Sackler | Polycyclohexose-polyoxyethyleneglycol suppository bases |
| JPS60106804A (ja) * | 1983-11-15 | 1985-06-12 | Nitto Boseki Co Ltd | ポリアリルアミンから誘導される新規な機能性樹脂 |
| US4908404A (en) * | 1988-08-22 | 1990-03-13 | Biopolymers, Inc. | Synthetic amino acid-and/or peptide-containing graft copolymers |
| SE467309B (sv) * | 1990-10-22 | 1992-06-29 | Berol Nobel Ab | Hydrofiliserad fast yta, foerfarande foer dess framstaellning samt medel daerfoer |
| ATE159262T1 (de) * | 1992-07-22 | 1997-11-15 | Hoechst Ag | Hydrophile zentren aufweisende polyvinylamin- derivate, verfahren zu ihrer herstellung sowie die verwendung der verbindungen als arzneimittel, wirkstoffträger und nahrungsmittelhilfsstoff |
| DK0580079T3 (da) * | 1992-07-22 | 1997-06-30 | Hoechst Ag | Tværbundne, nitrogenholdige vinylcopolymerer, fremgangsmåde til deres fremstilling samt anvendelse af disse forbindelser |
| DE4227019A1 (de) * | 1992-08-14 | 1994-02-17 | Geckeler Kurt E Priv Doz Dr | Herstellung und Modifikation von Materialien auf der Basis von Amino- oder Amidpolymeren |
| DE4322884A1 (de) * | 1992-10-09 | 1994-04-14 | Bayer Ag | Biologisch aktive Polymere |
| US5260385A (en) * | 1992-11-02 | 1993-11-09 | Director-General Of Agency Of Industrial Science And Technology | Biguanide group-containing polyallylamine and method of producing same |
| CA2167920A1 (en) * | 1993-07-23 | 1995-02-02 | Abraham J. Domb | Nonoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
| US5629184A (en) * | 1995-01-25 | 1997-05-13 | Amgen Inc. | Cationic copolymers of vinylamine and vinyl alcohol for the delivery of oligonucleotides |
-
1997
- 1997-12-12 FR FR9715807A patent/FR2766195A1/fr active Pending
-
1998
- 1998-07-20 AT AT98939713T patent/ATE215099T1/de not_active IP Right Cessation
- 1998-07-20 DE DE69804463T patent/DE69804463T2/de not_active Expired - Fee Related
- 1998-07-20 PT PT98939713T patent/PT998501E/pt unknown
- 1998-07-20 AU AU88131/98A patent/AU740392B2/en not_active Ceased
- 1998-07-20 CA CA002297487A patent/CA2297487A1/fr not_active Abandoned
- 1998-07-20 ES ES98939713T patent/ES2172180T3/es not_active Expired - Lifetime
- 1998-07-20 EP EP98939713A patent/EP0998501B1/fr not_active Expired - Lifetime
- 1998-07-20 US US09/463,249 patent/US6407178B1/en not_active Expired - Fee Related
- 1998-07-20 JP JP2000504174A patent/JP2001510863A/ja active Pending
- 1998-07-20 WO PCT/FR1998/001581 patent/WO1999005183A1/fr not_active Ceased
- 1998-07-20 DK DK98939713T patent/DK0998501T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2172180T3 (es) | 2002-09-16 |
| FR2766195A1 (fr) | 1999-01-22 |
| CA2297487A1 (fr) | 1999-02-04 |
| DE69804463T2 (de) | 2002-10-10 |
| US6407178B1 (en) | 2002-06-18 |
| AU740392B2 (en) | 2001-11-01 |
| US20020031763A1 (en) | 2002-03-14 |
| AU8813198A (en) | 1999-02-16 |
| EP0998501A1 (fr) | 2000-05-10 |
| DE69804463D1 (de) | 2002-05-02 |
| JP2001510863A (ja) | 2001-08-07 |
| PT998501E (pt) | 2002-08-30 |
| EP0998501B1 (fr) | 2002-03-27 |
| ATE215099T1 (de) | 2002-04-15 |
| WO1999005183A1 (fr) | 1999-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0998501T3 (da) | Kationiske polymerer, komplekser, som associerer de kationiske polymerer og terapeutisk aktive substanser, der omfatter mindst én negativ ladning, især nukleinsyrer, og anvendelse i genterapi | |
| ATE334664T1 (de) | Zelldurchlässige peptide zur inhibierung von entzündungsreaktionen und deren verwendung | |
| DE69943068D1 (de) | Transfer von mRNA unter Verwendung von polykationischen Verbindungen | |
| CA2045891A1 (en) | Oligonucleotide analogs with terminal 3'-3' or 5'-5' internucleotide linkages | |
| DE50006269D1 (de) | Kombinationen zur einführung von nucleinsäuren in zellen | |
| DE69528362D1 (de) | Oligomere phosphoramidat- und phosphorthioamidatverbindungen | |
| ATE218891T1 (de) | Nukleinsäurekomplex mit kationischen polymer nützlich für gentherapie | |
| FR2738151B1 (fr) | Antagonistes de l'activite oncogenique de la proteine mdm2, et leur utilisation dans le traitement des cancers | |
| DE59106279D1 (de) | Neue protein-polykation-konjugate. | |
| GR3006172T3 (da) | ||
| DE69132545D1 (de) | Protein mit Cytokinaktivität, Rekombinant-DNS, Expressionsvektor und Wirtszellen zu seiner Herstellung | |
| TR199801933A2 (xx) | Biyolojik olarak tolare edilebilen d���k molek�ler polietileniminler. | |
| CY1106041T1 (el) | Καινοφανης συλλεκτινη | |
| TR199802649A2 (xx) | Sikline ba�l� kinazlar�n inhibit�rleri i�in ba�lama e�leri. | |
| EP0689586A4 (en) | FUNCTION AND ACTIVITY OF VIRAL PROTEIN R (VPR) | |
| DE60044433D1 (de) | Transportproteine fuer organische anionen | |
| NO20011817D0 (no) | Ionebytte-tumormålsöking (IETT) | |
| ATE190621T1 (de) | Markierte, modifizierte oligonokleotiden | |
| ATE209506T1 (de) | Polyaminosäure-träger für oligonukleotid | |
| TR199902719T2 (xx) | Bile�ikler. | |
| ES468918A1 (es) | Procedimiento para la preparacion de complejos de peptido | |
| ATE376840T1 (de) | Gentherapeutika | |
| MXPA03001884A (es) | Agregados de proteina vp22/acido nucleico y uso de los mismos. | |
| CA2177600A1 (fr) | Sequences d'acides nucleiques regulatrices et utilisations | |
| WO2000063369A3 (en) | Gene therapy |